Kerry Carr
Nurse Practitioner · Jackson, WYNPI 1285716746
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,295 of the $19,381 with a category attached, or 78.9%. Johnson & Johnson accounts for 79.6% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2023 at $9,992 and has fallen 89.1% since, to $1,085 in 2025. Among nurse practitioner clinicians in WY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 114 payments — averaging $170.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$15K
- E.r. Squibb & Sons, L.L.C.$463
- AbbVie$435
- AstraZeneca$351
- EMD Serono, Inc.$286
- Regeneron Healthcare Solutions, Inc.$271
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$15,29579%
- Food & beverage$3,76019%
- Education$3262%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 9 | $15,435 |
| E.r. Squibb & Sons, L.L.C. | 8 | $463 |
| AbbVie(2 entities) | 10 | $435 |
| AstraZeneca | 6 | $351 |
| EMD Serono, Inc. | 5 | $286 |
| Regeneron Healthcare Solutions, Inc. | 3 | $271 |
| Pfizer | 10 | $189 |
| Bristol Myers Squibb | 4 | $175 |
| AVEO Pharmaceuticals, Inc. | 3 | $171 |
| Daiichi Sankyo Inc. | 7 | $161 |
| Exelixis Inc. | 1 | $135 |
| Merck | 6 | $134 |
| Seagen Inc. | 3 | $110 |
| Novartis | 5 | $102 |
| GSK | 1 | $101 |
| Incyte Corporation | 2 | $101 |
| Tempus AI, Inc | 3 | $82 |
| Genentech USA, Inc. | 3 | $74 |
| Eisai Inc. | 3 | $67 |
| Bayer | 3 | $62 |
| Amgen | 2 | $48 |
| Myovant Sciences Inc. | 2 | $45 |
| Myriad Genetic Laboratories, Inc. | 1 | $42 |
| Astellas Pharma US Inc | 2 | $41 |
| Medtronic | 1 | $41 |
| Gilead | 1 | $30 |
| Lilly USA, LLC | 1 | $30 |
| Sanofi | 1 | $29 |
| Stemline Therapeutics Inc. | 1 | $26 |
| Dova Pharmaceuticals | 1 | $24 |
| Genmab U.S., Inc. | 1 | $23 |
| Mirati Therapeutics, Inc. | 1 | $22 |
| Array Biopharma Inc | 1 | $22 |
| Adaptive Biotechnologies Corporation | 1 | $20 |
| Karyopharm Therapeutics Inc. | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,381 in reported general payments places this provider in the 95th percentile of 150 nurse practitioner providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 11 | $90,721 |
| Letrozole | 18 | $726 |
| Tamoxifen Citrate | 13 | $406 |
| Prochlorperazine Maleate | 13 | $100 |
| Lorazepam | 11 | $25 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $101 | $90,72111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 150 nurse practitioner providers in Wyoming.
Other nurse practitioner in Jackson
- Elizabeth DannewaldJackson$5K
- Krista SgroiJackson$1K
- Rebecca WhiteJackson$75
- Esther Gilman-KehrerLaramie$32K
- Jessica RodriguezLaramie$17K
- Kristin BrittCasper$5K
- Kerry FischerCasper$4K
- Molly RodrickCasper$3K
- Nichole TaylorGillette$3K
- Janine GloverCasper$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.